Blockade of Thrombopoietin Reduces Organ Damage in Experimental Endotoxemia and Polymicrobial Sepsis

Alessandra Cuccurullo1☯, Elisabetta Greco1☯, Enrico Lupia1☯, Paolo De Giuli2, Ornella Bosco1, Erica Martin-Conte3, Tiziana Spatola1, Emilia Turco4, Giuseppe Montrucchio1*

1 Department of Medical Sciences, University of Turin, Turin, Italy, 2 Anatomia Patologica, San Lazzaro Hospital, Alba, Italy, 3 Department of Anaesthesiology and Critical Care, University of Turin, Turin, Italy, 4 Department of Genetics, Biology and Biochemistry, University of Turin, Turin, Italy

☯ These authors contributed equally to this work.
* giuseppe.montrucchio@unito.it

Abstract

Background and Purpose

Thrombopoietin (TPO), a growth factor primarily involved in thrombopoiesis may also have a role in the pathophysiology of sepsis. In patients with sepsis, indeed, TPO levels are markedly increased, with disease severity being the major independent determinant of TPO concentrations. Moreover, TPO increases and correlates with ex vivo indices of platelet activation in patients with burn injury upon sepsis development, and may contribute to depress cardiac contractility in septic shock. Still, the role of TPO in sepsis pathophysiology remains controversial, given the protective role of TPO in other experimental disease models, for instance in doxorubicin-induced cardiotoxicity and myocardial ischemia/reperfusion injury. The aim of our study was to define the contribution of TPO in the development of organ damage induced by endotoxemia or sepsis, and to investigate the effects of inhibiting TPO in these conditions.

Methods

We synthesized a chimeric protein able to inhibit TPO, mTPOR-MBP, and studied its effect in two murine experimental models, acute endotoxemia and cecal ligation and puncture (CLP) model.

Results

In both models, TPO levels markedly increased, from 289.80±27.87 pg/mL to 465.60±45.92 pg/mL at 3 hours in the LPS model (P<0.01), and from 265.00±26.02 pg/mL to 373.70±26.20 pg/mL in the CLP model (P<0.05), respectively. Paralleling TPO levels, also platelet-monocyte aggregates increased, from 32.86±2.48% to 46.13±1.39% at 3 hours in the LPS model (P<0.01), and from 43.68±1.69% to 56.52±4.66% in the CLP model (P<0.05). Blockade of TPO by mTPOR-MBP administration reduced histological damage in target.
organs, namely lung, liver, and gut. In particular, neutrophil infiltration and lung septal thickening were reduced from a score of $1.86 \pm 0.34$ to $0.60 \pm 0.27$ ($P<0.01$) and from $1.43 \pm 0.37$ to $0.40 \pm 0.16$ ($P<0.05$), respectively, in the LPS model at 3 hours, and from a score of $1.75 \pm 0.37$ to $0.38 \pm 0.18$ ($P<0.01$) and from $1.25 \pm 0.31$ to $0.13 \pm 0.13$ ($P<0.001$), respectively, in the CLP model. Similarly, the number of hepatic microabscesses was decreased from $14.14 \pm 1.41$ to $3.64 \pm 0.56$ in the LPS model at 3 hours ($P<0.001$), and from $1.71 \pm 0.29$ to $0.13 \pm 0.13$ in the CLP model ($P<0.001$). Finally, the diameter of intestinal villi decreased from $90.69 \pm 3.95 \mu m$ to $70.74 \pm 3.60 \mu m$ in the LPS model at 3 hours ($P<0.01$), and from $74.29 \pm 4.29 \mu m$ to $57.50 \pm 1.89 \mu m$ in the CLP model ($P<0.01$). This protective effect was associated with the blunting of the increase in platelet-monocyte adhesion, and, on the contrary, with increased platelet-neutrophil aggregates in the circulation, which may be related to decreased neutrophil sequestration into the inflamed tissues. Conversely, circulating cytokine levels were not significantly changed, in both models, by mTPOR-MBP administration.

Conclusion

Our results demonstrate that TPO participates in the development of organ damage induced by experimental endotoxemia or polymicrobial sepsis via a mechanism involving increased platelet-leukocyte adhesion, but not cytokine release, and suggest that blocking TPO may be useful in preventing organ damage in patients affected by systemic inflammatory response or sepsis.

Introduction

Thrombopoietin (TPO), a growth factor primarily involved in regulating thrombopoiesis [1, 2], has recently emerged as a humoral mediator potentially implicated in the pathogenesis of sepsis [3].

TPO is constitutively produced by liver and kidneys, and cleared from the circulation by platelets upon binding to the TPO receptor c-Mpl, followed by internalization of the bound ligand [1, 2]. Its best characterized action is to stimulate platelet production by acting on megakaryocytic progenitor cells, as well as self-renewal and expansion of hematopoietic stem cells [4]. TPO also acts on cell types other than hematopoietic progenitors, exerting a variety of effects. In particular, TPO, although unable per se to induce platelet aggregation, enhances the response of mature platelets to several agonists [5, 6], and increases platelet-leukocyte adhesion via P-selectin [7], a phenomenon that has been associated with the development of acute coronary syndromes [8]. Moreover, TPO increases oxygen radical release and induces IL-8 production by neutrophils and monocytes [9]. Finally, TPO elicits various effects in other c-Mpl-expressing cells, including endothelial [10, 11], cardiac [12], and neuronal cells [13, 14].

Several studies have previously reported that TPO levels are increased after endotoxin infusion and in patients with sepsis [3], especially those with severe sepsis and septic shock [15]. TPO also increases in patients with burn injury upon sepsis development, and correlates with ex vivo indices of platelet activation, namely platelet P-selectin expression and increased platelet-monocyte adhesion [16], suggesting that TPO, by favoring platelet activation, may contribute to trigger multi-organ damage in these diseases [3]. Finally, TPO may depress cardiac contractility in septic shock, since it inhibits adrenergic receptor signal transduction in myocardiocytes, and cooperates with TNF-α and IL-1β to the cardio-depressant activity exerted in vitro by serum of septic shock patients [12]. Similar results, indicating TPO as a mediator of
organ damage, have also been reported in experimental models of acute lung injury [17] and acute pancreatitis [18]. However, other studies rather support a protective effect of TPO, for instance against cardiotoxicity induced by doxorubicin [19] and myocardial ischemia/reperfusion injury [20].

In this study, we aimed to define the role of TPO in the development of organ damage induced by experimental endotoxemia or polymicrobial sepsis, and to investigate the effects of inhibiting TPO in these conditions. To this end, we generated and characterized for its inhibiting activity against TPO a soluble recombinant chimeric protein, mTPOR-MBP, composed of the extracellular portion of mouse TPO receptor mTPOR/cMpl fused to the maltose-binding protein (MBP) in order to increase its solubility. We then studied whether TPO inhibition by mTPOR-MBP may reduce organ damage in two widely used experimental models, one mimicking a systemic inflammatory response syndrome, induced by i.p. injection of lipopolysaccharides (LPS), the other a model of abdominal infection leading to polymicrobial sepsis, represented by the cecal ligation and puncture (CLP) model.

**Materials and Methods**

**Synthesis of mTPOR-MBP**

We generated mTPOR-MBP by fusing the extracellular portion of mouse TPO receptor mTPOR/c-Mpl to maltose-binding protein (MBP). The DNA fragment encoding murine c-Mpl-extracellular domain (26–491) was amplified by PCR through high-fidelity DNA polymerase (Stratagene, La Jolla, CA), using 300 ng of murine c-Mpl cDNA (K.K. Dnaform, Ibaraki, Japan) as a template. The following primers were used: Forward 5′CCGGAATTCATGAGCCAAGATGTCTTCTTGCTGGCCT3′; Reverse 5′TGCTCTAGATTACAGGAGCAGAGCAGTCAC3′, carrying, at the 5′-end, the sequence for EcoRI and XbaI restriction enzymes, respectively. The amplification product was first digested with EcoRI and XbaI and purified on agarose gel. The 1425 bp PCR product was then sub-cloned into the expression vector pMal-c2 digested with EcoRI and XbaI (New England Biolabs, Ipswich, MA), downstream and in frame with the malE gene encoding MBP. Escherichia coli strain BL21(DE3)pLysS cells (Biocompare, Inc., South San Francisco, CA) was transformed with the vector. Protein expression was induced with 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 h at 37°C. Thereafter, cells were collected by centrifugation, frozen at -20°C, then thawed at 37°C, and lysed by sonication. The soluble fraction containing mTPOR-MBP fusion protein was loaded on a pre-packed amylose affinity column (New England Biolabs), and elution was performed with the same buffer supplemented with 10 mM maltose. mTPOR-MBP was finally dialysed against phosphate-buffered saline (PBS) and stored at -70°C.

Protein was analysed by SDS-PAGE on 8% polyacrylamide gel under reducing conditions, and transferred onto nitrocellulose. The membrane was blocked with 5% BSA in Tris-buffered solution containing Tween-20 (TBS-T) overnight at 4°C, followed by incubation with either antimurine c-Mpl monoclonal antibody (R&D Systems Inc., Minneapolis, MN), or anti-MBP rabbit polyclonal serum. Blots were probed with peroxidase-conjugated sheep anti-mouse (Amersham, Buckinghamshire, UK), or goat anti-rabbit (Pierce, Rockford, IL) antibodies, as appropriate, and developed with chemiluminescence reagents (PerkinElmer LAS, Boston, MA).

**Characterization of mTPOR-MBP**

Binding specificity of mTPOR-MBP with TPO was analysed by dot-blot as previously described [21]. Briefly, recombinant (r) TPO (R&D Systems Inc.) was diluted in PBS buffer (pH 7.4) at a concentration ranging from 3.12 µg/ml to 25 µg/ml. TNF-α and IL-1β (25 µg/ml, Sigma-Aldrich, St Louis, MO) were used as controls. 5 µl of each sample were spotted onto a
nitrocellulose membrane, then blocked with 5% BSA in TBS-T buffer for 1 hour. The membrane was incubated with the mTPOR-MBP (0.5 μg/ml) overnight at 4°C, and subsequently with anti-murine c-Mpl/TPOR monoclonal antibody for 2 hours at room temperature. Blots were probed with peroxidase-conjugated sheep anti-mouse antibody and developed with chemiluminescence reagents.

The ability of mTPOR-MBP to block TPO biological activity in vitro was tested by using a short-term proliferative assay on the megakaryoblast cell line M-07 [22] and platelet aggregation experiments in platelet-rich plasma (PRP) [5].

For the proliferative assay, 2x10^5 M-07 cells were plated in a 96-wells microplate and stimulated with rTPO (50–1000 pg/ml), in the presence or absence of mTPOR-MBP (1–20 μg/ml) for 48 hours. Afterwards each well was pulsed with 1 μC of tritiated thymidine (Amersham) allowing incorporation for 16 hours. Cells were then harvested, and thymidine incorporation was determined in a scintillation counter after addition to each vial of 1mL of scintillation liquid.

For platelet aggregation experiments, blood was collected by clean venipuncture using a 19-gauge butterfly infusion set, without venous stasis, from healthy adult donors, who had not taken any medications for at least 2 weeks. Nine volumes of blood were withdrawn in 1 vol of 3.8% trisodium citrate. PRP was prepared by centrifugation for 15 minutes at 180g. Platelet poor plasma (PPP) was obtained by centrifugation at 2,000g for 10 minutes. Platelet aggregation in PRP was evaluated according to the Born’s method [23], at 37°C with constant rate of stirring at 1,000 rpm in a lumi-aggregometer (Chronolog, Havertown, PA) using PPP as reference, setting to 0% the light transmission using PRP and to 100% using PPP. The maximal aggregation was quantified according to the Weiss formula [24]. PRP samples were incubated with 100 pg/ml rTPO for 5 minutes, before epinephrine (EPI; Helena Laboratories, Beaumont, TX), as secondary agonist, was added. For each experiment, the concentration of EPI that induced the minimum measurable aggregation was determined (0.1–1 μmol/L). The priming index (PI) was calculated as the response to rTPO and EPI together, divided by the sum of individual responses elicited by rTPO and EPI separately. Using this calculation, a PI > 1 indicated synergism, a PI = 1 indicated additive response, and PI < 1 indicated inhibition [5,16]. In separate experiments, rTPO was pre-incubated with the mTPOR-MBP, or purified MBP as control (2 μg/ml each), for 5 minutes at 37°C; the mixture of rTPO and mTPOR-MBP or purified MBP was added to PRP, further incubated for 5 minutes at 37°C and stimulated with EPI.

In preliminary experiments, mice were injected i.p. with 40 μg of mTPOR-MBP, and, for the next 24 hours, the presence of mTPOR-MBP in plasma was checked. Briefly, blood was drawn by the tail vein, centrifuged at 600g for 10 minutes in order to obtain plasma, and the presence of mTPOR-MBP was detected by western blot analysis, using the anti-MBP rabbit polyclonal serum.

Experimental models

Three month-old male C57BL/6 mice were used for all experiments (the exact n/group distributions are specified in the figure legends). Mice were kept together in groups of five per cage, housed on a 12 h light-dark diurnal cycle with controlled temperature (21°C to 23°C) and provided with standard rodent diet and water ad libitum.

Acute endotoxemia was induced by i.p. injection with 40 mg/kg of LPS from E. coli 0111:B4 (Sigma-Aldrich) in a volume of 250 μl sterile saline solution [25]. A separate group of animals received an i.p. injection of 40 μg of mTPOR-MBP in a volume of 200 μl sterile saline solution, 10 minutes after LPS administration. As controls, separate groups of mice received the same concentration of mTPOR-MBP alone, MBP alone, and/or sterile saline solution.
To confirm the results obtained with LPS injection, we used a second model of polymicrobial sepsis induced by cecal ligation and puncture (CLP) [26]. Mice were anesthetized with tiletamine (80 mg/kg), and a midline abdominal incision was performed. The cecum was mobilized, ligated below the ileo-cecal valve, and punctured twice with a 25-gauge needle. The abdomen was then closed in two layers, and the mice injected s.c. with 1.0 ml 0.9% saline. A separate group of animals received an i.p. injection of 40 μg of mTPOR-MBP in a volume of 200 μl sterile saline solution, 30 minutes after surgery was completed. As controls, separate groups of mice received the same concentration of MBP alone and/or sterile saline solution. Sham-operated mice were handled in the same manner, except the cecum was neither ligated nor punctured.

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, as well as institutional guidelines and Italian government regulations. The protocol was approved by the Institutional Review Committee for Animal Care and Use at the University of Turin (Protocol Number: 0008619-P). All surgery was performed under anesthesia, and all efforts were made to minimize suffering. In particular, buprenorphine (0.05 mg/kg i.p.) was administered before surgery as well as 6 hours after surgery to reduce postoperative pain, and animals were inspected for signs of illness and/or unusual behavior by research staff at least once per day. Whenever an animal's condition deteriorated (defined by, among other parameters, decreased activity, and rapid weight gain) followed by the appearance of signs of imminent death (i.e. inability to maintain upright position/ataxia/tremor and/or agonal breathing) mice were killed by using deep inhalation anesthesia (isoflurane) followed by an overdose of barbiturate (thiopental). The percentage of premature deaths in both models did not exceed 10%.

Sample collection and cell counts
At the indicated times (basal, 3, and 6 hours after LPS injection, and after 18 hours in the CLP model), mice were anesthetized with tiletamine (80 mg/kg), and blood samples were collected from the inferior cava vein into tubes containing trisodium citrate (0.11 mol/liter). The examined time-points have been chosen on the basis of preliminary experiments performed in our laboratory, and of similar studies already published in the literature [25, 27, 28]. Blood was used for platelet and white blood cell counting, using an automated counter, for flow cytometry analysis, and to obtain plasma, after centrifugation at 600g for 10 minutes. Soon after, liver and small intestine were rapidly dissected and fixed in 4% neutral buffered formalin for histological analysis. A polyvinyl catheter was then secured in the trachea, and used to instil 4% neutral buffered formalin into the lungs at a hydrostatic pressure of 30 cmH2O. Portions of the formalin-distended lungs were harvested and used for histological analysis.

Histological analysis
Histological damage was evaluated on H&E-stained 5 μm paraffin sections by an expert pathologist (P.D.G.) blind to the sample identity. To measure lung injury, neutrophil infiltration and alveolar-capillary membrane thickening were scored by assigning a subjective value from zero (absent) to three (extensive) scale. In each tissue sample, five random fields were scored, and the mean value was calculated.

To evaluate liver injury, the number of leukocyte microabscesses, i.e. discrete neutrophil infiltrates around the portal veins that derive from neutrophil infiltration within the liver parenchyma [25], was counted in 10 randomly-selected fields.

Gut injury was evaluated by measuring intestinal villus thickness in 5 randomly-selected fields.
TPO and cytokine measurement

TPO levels in plasma were determined by ELISA (R&D Systems Inc.) according to the manufacturer’s recommendations, with the exception of a 3-fold plasma dilution.

Cytokine (TNF-α, IL-6, and IL-10) concentrations were measured in plasma samples using a fluorescent bead–based multiplex immunoassay (Bio-plex®/Luminex®, Luminex Co., Austin, TX), as previously described [29, 30].

Flow cytometry

Leukocyte-platelet aggregates ex vivo were analyzed by two-colour staining of whole blood samples. Briefly, blood was collected, diluted 1:1 with Tyrodes’s Hepes-buffered saline (pH 7.4), and incubated 15 minutes at room temperature with a mixture of PE-Cy5-conjugated anti-mouse-CD45 monoclonal antibody (eBioscience, San Diego, CA), which binds all leukocytes, and FITC-conjugated anti-mouse-CD41 (Serotec, Raleigh, U.S.A.) monoclonal antibody, which identifies platelets. Cells were then fixed with 1% paraformaldehyde and erythrocytes were removed by hypotonic lysis. Samples were washed twice with PBS-BSA 0.1% and resuspended in 0.5 ml PBS. Samples were analyzed on a EPICS–XL flow cytometer (Beckman Coulter Corp, Hialeah, FL). Total leukocytes were identified by their positive staining with anti-CD45 in the CD45 versus side scatter dot plot, whereas lymphocyte, neutrophil and monocyte populations were discriminated by size and granularity in the forward scatter versus side scatter dot plot using a logic gate. The percentage of monocyte-platelet or neutrophil-platelet aggregates, therefore co-expressing both markers CD45 and CD41 over the total number of cells counted within the logic gates previously selected was calculated and used as an index of platelet-monocyte or platelet-neutrophil adhesion.

Analysis of data

Data are expressed as mean ± S.E.M. Comparisons between groups were analyzed by ANOVA followed by Newman-Keul’s multicomparison test or by Student’s t test, where appropriate. Relationship between variables was investigated by Spearman rank correlation coefficient.

A P value < 0.05 was considered significant.

All statistics were done with GraphPad Prism 4.00 for Windows (GraphPad Software, La Jolla, CA, USA).

Results

Synthesis and characterization of mTPOR-MBP

Aiming to block TPO actions in vivo, we designed and synthesized a chimeric protein, mTPOR-MBP, originated by the fusion of the extracellular portion of mTPOR/c-Mpl and of MBP, used to enhance its solubility. The soluble form of mTPOR-MBP was purified by affinity chromatography using an amylose column, and recognized by antibodies directed against MBP and TPOR/c-Mpl by western blot. mTPOR-MBP showed dose-dependent high-affinity binding for rTPO in dot-blot assay, whereas it did not recognized TNF-α and IL-1β (Fig 1A). In addition, it reduced the proliferation induced by rTPO in M-07 cells (Fig 1B) [22], and the priming effect exerted by rTPO on epinephrine-induced platelet aggregation in PRP (Fig 1, panels C and D) [5, 8]. mTPOR-MBP inhibitory effect on platelet aggregation was dose-dependent, and reached a plateau at a concentration of 1.5–2 μg/ml in the presence of 100 pg/ml of rTPO. mTPOR-MBP alone did not induce any effect neither on M-07 cell proliferation nor on platelet aggregation (not shown). Finally, once-daily administration was chosen on the basis of the presence of mTPOR-MBP in mouse plasma, as detected by Western blot analysis, up to 24 hours after i.p. administration (Fig 1E).
TPO concentrations increased in experimental endotoxemia and polymicrobial sepsis

Previous studies have shown that TPO levels are increased after endotoxin infusion and in patients with sepsis [3, 15]. Here, we analyzed whether TPO levels were also increased in an acute endotoxemia model and in the CLP model. In acute endotoxemia induced by LPS i.p.
Injection, TPO concentrations increased at 3 hours from LPS administration, both in comparison to basal levels, and to those measured in mice injected with saline, and decreased at 6 hours to concentrations lower than those measured at time 0 and after 3 hours (Fig 2A). Also in the CLP model, TPO levels were significantly increased in septic mice compared to those measured in sham-operated mice (Fig 2B).

**mTPOR-MBP reduces organ damage in experimental endotoxemia and polymicrobial sepsis**

It is known that sepsis mortality is strictly related to the development of injury and failure in target organs [31]. In both models investigated, the induction of systemic inflammation or sepsis was associated with the development of severe histological lesions in the target organs, which were significantly reduced by mTPOR-MBP administration.

The effect of mTPOR-MBP on the development of organ damage induced by LPS administration was evaluated at 3 and 6 hours (Figs 3 and 4). Lung injury, evaluated by measuring neutrophil infiltration and alveolar septal thickening, was significantly reduced by mTPOR-MBP at both time-points (Fig 3).

Moreover, mTPOR-MBP reduced the number of hepatic micro-abscesses around the centrolobular veins, consequent to massive infiltration of inflammatory cells into the hepatic parenchyma, at both 3 and 6 hours from LPS injection (Fig 4, panels A and B). Finally, mTPOR-MBP prevented the development of intestinal injury, which led to increased diameter of villi, secondary to leukocyte recruitment and edema, at both time-points (Fig 4, panel C and D).

Also in the CLP model, mTPOR-MBP significantly reduced the severity of tissue injury induced in lung, liver and gut (Figs 5 and 6).

mTPOR-MBP alone did not show any effect on lung, liver and gut histology in both models (not shown).

**mTPOR-MBP does not affect cytokine release in experimental endotoxemia and polymicrobial sepsis**

In severe sepsis pathophysiology, intense pro-inflammatory reactions, which includes the secretion and release of several cytokines in blood, are usually associated with the development of...
of collateral tissue damage and consequent organ failure [31]. As expected, the induction of systemic inflammation or sepsis was associated with a relevant increase in circulating cytokine concentrations in both models studied (Fig 7). Plasma levels of TNF-α, IL-6, and IL-10 were strongly increased after 3 and 6 hours from LPS administration, as well as after sepsis induction in the CLP model, in comparison to those measured in saline-injected or sham-operated mice.

Fig 3. Effect of mTPOR-MBP on the development of lung damage in the LPS model. (A) Representative micrographs of lung histology in LPS-injected mice untreated (upper panel) or treated (lower panel) with mTPOR-MBP at the indicated time-points (see Materials and Methods for experimental details). Original magnification, X200. Black bars, 50 μm. (B) Quantification of neutrophil infiltration within lung septa after LPS administration, in mice treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for methodological details). (C) Quantification of lung septal thickening after LPS administration, in mice treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for methodological details). The number of animals studied per experimental group was as follows: Control (C) = 6; mTPOR-MBP alone = 5; LPS 3h = 7; LPS 3h + mTPOR-MBP = 10; LPS 6h = 6; LPS 6h + mTPOR-MBP = 5. * P < 0.05; ** P < 0.01.

doi:10.1371/journal.pone.0151088.g003
Fig 4. **Effect of mTPOR-MBP on the development of liver and intestinal damage in the LPS model.** (A) Representative micrographs of liver histology in LPS-injected mice untreated (upper panel) or treated (lower panel) with mTPOR-MBP at the indicated time-points (see Materials and Methods for experimental details). Original magnification, X200. Black bars, 50 μm. (B) Quantification of hepatic micro-abscesses after LPS administration, in mice treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for methodological details). (C) Representative micrographs of gut histology in LPS-injected mice untreated (upper panel) or treated (lower panel) with mTPOR-MBP at the indicated time-points (see Materials and Methods for experimental details). Original magnification, X200. Black bars, 50 μm. (D) Quantification of intestinal villus diameter after LPS administration, in mice treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for methodological details). The number of animals studied per experimental group was as follows: Control (C) = 6; mTPOR-MBP alone = 5; LPS 3h = 7; LPS 3h + mTPOR-MBP = 10; LPS 6h = 6; LPS 6h + mTPOR-MBP = 5. * P < 0.05; ** P < 0.01; *** P < 0.001.

doi:10.1371/journal.pone.0151088.g004
Quite surprisingly though, mTPOR-MBP did not induce any significant change in cytokine levels neither in the LPS model at both time-points examined (Fig 7, panels A-C), nor in the CLP model, although a tendency toward a reduction in TNF-α levels was observed in this model (Fig 7, panels D-F).

mTPOR-MBP alone did not show any effect on cytokine levels (not shown).

mTPOR-MBP modulates platelet-leukocyte adhesion in experimental endotoxemia and polymicrobial sepsis

Sepsis development has been associated with the appearance in the circulation of increased platelet-monocyte and platelet-neutrophil aggregates, which are believed to have a relevant role in the progression to the most severe forms of the disease [31]. In particular, platelet-monocyte adhesion is considered an early and sensitive measure of platelet activation [32], while platelet-neutrophil interaction has a crucial role in the recruitment of neutrophils to
inflamed tissues and in the development of target organ injury [33]. Therefore, we studied the effects of mTPOR-MBP administration on platelet-leukocyte adhesion in both experimental models.

In the LPS model, both platelet-monocyte and platelet neutrophil aggregates increased at 3 hours, and decreased to levels lower than basal values at 6 hours from LPS injection (Fig 8, panels A-C). The temporal trend of platelet-leukocyte adhesion closely paralleled that of TPO release in the circulation of LPS-treated mice. Furthermore, we found a significant correlation

**Fig 6. Effect of mTPOR-MBP on the development of liver and intestinal damage in the cecal ligation and puncture (CLP) model.** (A) Representative micrographs of liver histology in sham-operated mice and septic mice 18 hours after CLP, treated or not with mTPOR-MBP (see Materials and Methods for experimental details). Original magnification, X200. Black bars, 50 μm. (B) Quantification of hepatic micro-abscesses in sham-operated mice (white columns) and septic mice 18 hours after CLP, treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for methodological details). (C) Representative micrographs of gut histology in sham-operated mice and septic mice 18 hours after CLP, treated or not with mTPOR-MBP (see Materials and Methods for experimental details). Original magnification, X200. Black bars, 50 μm. (D) Quantification of intestinal villus diameter in sham-operated mice (white columns) and septic mice 18 hours after CLP, treated (dashed columns) or not (black columns) with mTPOR-MBP (see Materials and Methods for methodological details). The number of animals studied per experimental group was as follows: Sham-operated mice = 10; CLP = 8; CLP + mTPOR-MBP = 8. * P < 0.05; ** P < 0.01; *** P < 0.001.

doi:10.1371/journal.pone.0151088.g006
between TPO levels and platelet-monocyte adhesion \((r = 0.5185, P < 0.05)\), and between TPO levels and platelet-neutrophil adhesion \((r = 0.6805, P < 0.001)\) measured ex vivo. mTPOR-MBP administration significantly blunted the increase in both platelet-monocyte and platelet-neutrophil adhesion observed at 3 hours from LPS administration (Fig 8, panels B and C). On the contrary, the percentage of both platelet-monocyte and platelet-neutrophil aggregates were higher in endotoxemic mice treated than in those untreated with mTPOR-MBP after 6 hours from LPS injection (Fig 8, panels B and C).

Analogously to what we observed in the LPS model, also in the CLP model platelet-monocyte adhesion was enhanced after sepsis induction in comparison to that measured in sham-operated mice (Fig 8D), showing a temporal trend similar to that of TPO release in the circulation. However, no correlation was found between TPO and platelet-monocyte adhesion in this model. Moreover, mTPOR-MBP administration was associated with a significant reduction in the percentage of platelet-monocyte aggregates, to levels similar to those detected in sham-operated mice (Fig 8D). On the contrary, platelet neutrophil binding in septic mice did not differ from the levels observed in sham-operated mice, at least at the time-point examined (Fig 8E), while the administration of mTPOR-MBP was associated with an evident increase in circulating platelet-neutrophil aggregates in septic mice (Fig 8E).
Fig 8. Effect of mTPOR-MBP on platelet-leukocyte adhesion in LPS model and in the cecal ligation and puncture (CLP) model. (A) Representative flow cytometry analysis of platelet-monocyte (upper lane) and platelet-neutrophil aggregates (lower lane) detected in mice injected with saline (Control) and in mice injected with LPS treated or not with mTPOR-MBP. The two left panels show an example of monocyte (upper panel) and neutrophil (lower panel) subpopulations, identified by size and granularity in the forward scatter (FS LIN) versus side scatter (SS LIN) dot plot, using a logic gate, over the total CD45-positive leukocyte population. The others panels are representative of CD45 versus CD41 dot plots obtained in the different experimental conditions.
No change in platelet-leukocyte adhesion was detected in mice injected with saline or mTPOR-MBP alone in both experimental models. Finally, the induction of systemic inflammation or sepsis was associated with a relevant decrease in leukocyte and platelet counts in both models, an effect that was neither observed in mice injected with saline or mTPOR-MBP alone, nor in sham-operated mice (Fig 9). The administration of mTPOR-MBP did not prevent the drop in leukocyte and platelet count at 3 hours from LPS injection, and had only a modest effect on leukocyte count, which resulted higher in LPS-treated mice than controls, but not on platelet count, at 6 hours (Fig 9, panels A and B). No effect on leukocyte and platelet count drop was observed after mTPOR-MBP administration in the CLP model either (Fig 9, panels C and D).

Discussion

The aim of this study was to define the contribution of TPO in enhancing platelet-leukocyte adhesion associated with systemic inflammation and sepsis, and to explore the potential therapeutic effect of TPO blockade in inhibiting the development of organ damage in an acute endotoxemia model, which mimics a systemic inflammatory response syndrome, and in the CLP model, which is an abdominal infection model that leads to polymicrobial sepsis. Therefore, we synthesized a chimeric protein, mTPOR-MBP, and characterized it for its ability to inhibit in vivo the biological activity of TPO. We then tested its effects in these two widely used murine experimental models.

Until now, the involvement of systemic inflammation or sepsis was associated with a relevant decrease in leukocyte and platelet counts in both models, an effect that was neither observed in mice injected with saline or mTPOR-MBP alone, nor in sham-operated mice (Fig 9). The administration of mTPOR-MBP did not prevent the drop in leukocyte and platelet count at 3 hours from LPS injection, and had only a modest effect on leukocyte count, which resulted higher in LPS-treated mice than controls, but not on platelet count, at 6 hours (Fig 9, panels A and B). No effect on leukocyte and platelet count drop was observed after mTPOR-MBP administration in the CLP model either (Fig 9, panels C and D).
pathophysiology of human sepsis, associated with the activation of a number of host mediator systems [34], whereas endotoxemia induced by LPS injection, rather mimics a systemic inflammatory response syndrome, usefully allowing to more precisely study the time-course of the inflammatory events elicited by LPS. Therefore, it may be hypothesized that TPO may be involved in triggering the early phase of platelet-leukocyte adhesion, which could be later sustained, at least in sepsis, by other mediators.

The administration of mTPOR-MBP inhibited the increase of platelet-monocyte binding both in the LPS model at three hours and in the CLP model, definitively showing that high
TPO levels represent a pivotal stimulus of platelet activation and platelet-monocyte aggregation in these two models. On the contrary, mTPOR-MBP administration was associated with the persistence of platelet-neutrophil aggregates in the circulation at levels higher than in untreated mice, both in the LPS model at 6 hours and in the CLP model. Several studies have previously shown that platelet activation and thrombocytopenia are associated with the development of organ dysfunction during sepsis and with increased sepsis severity [35–37]. Frequent abnormalities in platelet count have been, indeed, reported, and sepsis severity correlates with the decrease in platelet count [35–40]. Furthermore, circulating platelets are activated in experimental sepsis models, as well as in septic patients [35–37, 41–44], a phenomenon that can predispose to micro-thrombotic events, which may reduce organ perfusion and participate in microcirculatory dysfunction [45–50]. In addition, sepsis development has been associated with increased surface expression of platelet adhesion molecules, and increased circulating platelet-monocyte aggregates, which are considered not only a sensitive measure of platelet activation, but also have major pro-inflammatory and pro-thrombotic consequences [32].

Finally, a link between platelet-leukocyte, in particular platelet-neutrophil adhesion, and clinical outcome has been reported in septic patients [33, 42–44]. Platelet-neutrophil aggregates, which are required for the recruitment of neutrophils to inflamed tissues [33], increase, indeed, upon sepsis development, but decrease in those patients who develop organ failure and eventually die [42, 44]. This phenomenon is considered expression of the increased recruitment of neutrophils to inflamed tissues and peripheral sequestration, which may be implicated in the development of sepsis-induced multiple organ dysfunction syndrome [33, 42, 44]. Therefore, the increase of platelet-neutrophil adhesion observed in our study at later time-points after mTPOR-MBP administration may reflect the inhibition of platelet activation and adhesion to leukocytes and, consequently, of platelet-neutrophil aggregates to the endothelium, which may be implicated in the protective effect of TPO blockade on inflammation- or sepsis-induced organ-damage. These results are in agreement with those of previous experimental studies that suggest that inhibiting platelet activation may reduce sepsis-related mortality. For instance, platelet depletion had a protective effect in CLP model [51–53], and the modulation of platelet activation by using specific anti-P-selectin antibody [53] or drugs that inhibit platelet activation, such as clopidogrel, was beneficial [54] both in endotoxin shock [54] and polymicrobial sepsis [55], leading to hypothesize that anti-platelet drugs may represent a potential treatment in sepsis or acute respiratory distress syndrome [56].

In our study, we observed a dramatic reduction in leukocyte and platelet counts in both models, which was not prevented by mTPOR-MBP. Therefore, this well-described phenomenon is not related to TPO activity, but rather to the direct action of LPS on leukocytes, and, may be, platelets themselves. However, this observation excludes that the decrease in platelet-leukocyte aggregation we detected with mTPOR-MBP may be caused by the drop in leukocyte and platelet absolute counts.

Quite surprisingly, mTPOR-MBP was not able to inhibit the increase in plasma concentrations of TNF-α, IL-6 and IL-10 observed in both models, a well-known phenomenon that participates in the initiation and progression of organ damage during systemic inflammation and sepsis [31]. Therefore, our data shows that TPO inhibition by mTPOR-MBP exerts its protective effect on organ damage primarily by influencing platelet-leukocyte adhesion, while it does not affect cytokine release. Similar results, i.e. a dissociation between the protective effect on sepsis-related mortality and cytokine increased production, were previously described, in a model of endotoxin shock, with the administration of erythropoietin, another hematopoietic growth factor/cytokine [57]. This observation has interesting implications for our knowledge of sepsis pathogenesis, since it suggests that the development of sepsis-induced organ damage and cytokine release may not be necessarily related. However, our experimental data cannot
exclude that the inhibition by mTPOR-MBP of other TPO actions, for instance the ability to stimulate the production of oxygen radicals or IL-8 from leukocytes, or to modulate apoptosis in several cell types [3], may also have had a role in the effects observed in our study. Finally, another intriguing hypothesis may be evoked to explain the protective effect of TPO blockade in these experimental models. We have previously shown that high TPO concentrations in plasma samples from patients with septic shock cooperate with TNF-α and IL-1β in depressing myocardial contractility [12]. Therefore, we could hypothesize that blocking TPO in vivo by a selective antagonist as mTPOR-MBP could inhibit the priming effect of TPO on the activity of other mediators, such as inflammatory cytokines, thus dampening the development of damage to target organs.

We cannot precisely define the origin of the rise in TPO levels observed in our study after the induction of acute endotoxemia and polymicrobial sepsis. Platelet mass is considered the primary regulator of TPO levels [4], and both endotoxemic and septic animals had a profound thrombocytopenia, together with increased indices of ex vivo platelet activation. Platelets themselves, which are known to release active TPO upon stimulation [58], could also be a major source for TPO release. Finally, high TPO levels may derive from increased hepatic synthesis, since IL-6 enhances TPO synthesis from hepatocytes [59]. However, this last possibility can be excluded in the LPS model, on the basis of the kinetic of TPO appearance in mouse plasma, too rapid to implicate protein synthesis.

Several limits have to be taken into account in interpreting our results. First, we did not evaluate the effect of TPO inhibition on long-term organ protection, neither on survival and recovery in both models. Therefore, we cannot exclude that the observed effects of mTPOR-MBP administration are transient, and/or that TPO inhibition has not a significant impact on disease evolution. Second, we cannot provide a clear demonstration of the mechanistic effect of TPO in the pathophysiology of systemic inflammation or sepsis. Although intriguing, the link between the observed effects of TPO inhibition on platelet-leukocyte interaction and the development of inflammation- or sepsis-associated tissue damage in target organs still remains not definitely proven by our experiments.

In conclusion, blockade of TPO biological activity significantly reduced the severity of organ damage in both experimental endotoxemia and polymicrobial sepsis. This protective effect is associated with the inhibition of the increase in platelet-leukocyte adhesion, but not of cytokine release, observed during systemic inflammation and sepsis. Our results support the need to further explore the possibility of inhibiting TPO in the intent to prevent or reduce organ damage in patients affected by systemic inflammatory response or sepsis.

Author Contributions
Conceived and designed the experiments: EL ET GM. Performed the experiments: AC EG OB EM-C TS. Analyzed the data: AC EG EL PDG OB ET GM. Wrote the paper: AC EG EL PDG OB ET GM.

References
1. Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. J Thromb Haemost. 2003; 1 (7):1587–92. PMID: 12871295.
2. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002; 100(10):3457–69. PMID: 12411315.
3. Lupia E, Goffi A, Bosco O, Montruccchio G. Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases. Mediators Inflamm. 2012; 2012:390892. Epub 2012/05/12. doi: 10.1155/2012/390892 PMID: 22577249.
4. Chou FS, Mulloy JC. The thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis. J Cell Biochem. 2011; 112(6):1491–8. Epub 2011/03/02. doi: 10.1002/jcb.23089 PMID: 21360575.
5. Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood. 1996; 87(7):2762–8. PMID: 8639892.

6. Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood. 1996; 87(11):4664–70. PMID: 8639835.

7. Tibbles HE, Navara CS, Hupke MA, Vassilev AO, Uckun FM. Thrombopoietin induces p-selectin expression on platelets and subsequent platelet/leukocyte interactions. Biochem Biophys Res Commun. 2002; 292(4):987–91. PMID: 11944912.

8. Lupia E, Bosco O, Bergerone S, Dondi AE, Goffi A, Oliaro E, et al. Thrombopoietin contributes to enhanced platelet activation in patients with unstable angina. J Am Coll Cardiol. 2006; 48(11):2195–203. PMID: 17161245.

9. Brizzi MF, Battaglia E, Rosso A, Strippoli P, Montrucchio G, Camussi G, et al. Regulation of polymorphonuclear cell activation by thrombopoietin. J Clin Invest. 1997; 99(7):1576–84. PMID: 9120001.

10. Brizzi MF, Battaglia E, Montrucchio G, Dentelli P, Del Sorbo L, Garbarino G, et al. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circulation research. 1999; 84(7):785–96. PMID: 10205146.

11. Ramella R, Gallo MP, Sapatola T, Lupia E, Alloatti G. A novel role of thrombopoietin as a physiological modulator of coronary flow. Regul Pept. 2011; 167(1):5–8. Epub 2011/01/18. S0167-0115(11)00003-6 [pii] doi: 10.1016/j.regpep.2010.12.008 PMID: 21237210.

12. Lupia E, Spatola T, Cuccurullo A, Bosco O, Mariano F, Pucci A, et al. Thrombopoietin modulates cardiac contractility in vitro and contributes to myocardial depressing activity of septic shock serum. Basic research in cardiology. 2010; 105(5):609–20. Epub 2010/05/15. doi: 10.1007/s00395-010-0103-6 PMID: 20467749.

13. Ehrenreich H, Hasselblatt M, Kernich F, von Ahsen N, Jacob S, Sperling S, et al. A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. Proc Natl Acad Sci U S A. 2005; 102(3):862–7. Epub 2005/01/12. 0406008102 [pii] doi: 10.1073/pnas.0406008102 PMID: 15642952.

14. Ivanova A, Wuerfel J, Zhang J, Hoffmann O, Ballmaier M, Dame C. Expression pattern of the thrombopoietin receptor (Mpl) in the murine central nervous system. BMC Dev Biol. 2010; 10:77. Epub 2010/07/30. 1471-213X-10-77 [pii] doi: 10.1186/1471-213X-10-77 PMID: 20667107.

15. Zakynthinos SG, Papapikolaou S, Theodoridis T, Zakynthinos EG, Christopoulou-Kokkinou V, Katsaris G, et al. Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients. Critical care medicine. 2004; 32(4):1004–10. PMID: 15071393.

16. Lupia E, Bosco O, Mariano F, Dondi AE, Goffi A, Spatola T, et al. Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation. J Thromb Haemost. 2009; 7(6):1000–8. PMID: 19317837. doi: 10.1111/j.1538-7836.2009.03348.x

17. Del Sorbo LFV, Muraca G, Martin EL, Lutri L, Costamagna A, Assenzo B, Lupia E, Montrucchio G, Ranieri VM. Thrombopoietin may enhance ventilator-induced lung injury. Crit Care 2011; 15(1):207.

18. Shen J, Wan R, Hu G, Wang F, Wang X. Involvement of thrombopoietin in acinar cell necrosis in L-arginine-induced acute pancreatitis in mice. Cytokine. 2012; 60(1):294–301. Epub 2012/06/16. S1043-4666(12)00186-X [pii] doi:10.1016/j.cyto.2012.05.005 PMID: 22698803.

19. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM, et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation. 2006; 113(18):2211–20. PMID: 16651473.

20. Baker JE, Su J, Hsu A, Shi Y, Zhao M, Strande JL, et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc Res. 2008; 77(1):44–53. PMID: 18006466.

21. Zhang Q, Pan R, Hu M, Xu P. Expression of the soluble extracellular domain of human thrombopoietin receptor using a maltose-binding protein-affinity fusion system. Biological & pharmaceutical bulletin. 2004; 27(2):219–21. PMID: 14758037.

22. Avanz GC, Brizzi MF, Giannotti J, Ciarletta A, Yang YC, Pegoraro L, et al. M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3. Journal of cellular physiology. 1999; 145(3):458–64. PMID: 2273055.

23. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962; 194:927–9. Epub 1962/06/09. PMID: 13871375.

24. Weiss HJ, Rogers J. Thrombocytopathia due to abnormalities in platelet release reaction—studies on six unrelated patients. Blood. 1972; 39(2):187–96. Epub 1972/02/01. PMID: 5009024.

25. Corral J, Yelamos J, Hernandez-Espinosa D, Monreal Y, Mota R, Arcas I, et al. Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant...
mice models. Am J Pathol. 2005; 166(4):1089–98. Epub 2005/03/29. S0002-9440(10)62329-2 [pii] doi: 10.1016/S0002-9440(10)62329-2 PMID: 15793289.

26. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc. 2009; 4(1):31–6. Epub 2009/01/10. nprot.2008.214 [pii] doi: 10.1038/nprot.2008.214 PMID: 19131954.

27. Gonzalez-Rey E, Chorny A, Robledo G, Delgado M. Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. The Journal of experimental medicine. 2006; 203(3):563–71. Epub 2006/02/24. jem.20052017 [pii] doi: 10.1084/jem.20052017 PMID: 16492802.

28. Levi M, Dvorfl-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003; 101(12):4823–7. Epub 2003/03/01. doi: 10.1182/blood-2002-10-3254 2002-10-3254 [pii]. PMID: 12609841.

29. Zou L, Feng Y, Li Y, Zhang M, Chen C, Cai J, et al. Complement factor B is the downstream effector of Toll-like Receptor 4 Is Essential to Pre-

30. Zou L, Feng Y, Chen YJ, Zhou Q, Ichinose F, et al. Toll-like Receptor 4 Is Essential to Pre-

31. Yaguchi A, Lobo FL, Vincent JL, Pradier O. Platelet function in sepsis. J Thromb Haemost. 2004; 2

32. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation. 2002; 105(18):2130–2. PMID: 11994242.

33. Page C, Pitchford S. Neutrophil and platelet complexes and their relevance to neutrophil recruitment and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides. Thromb Haemost. 2004; 91(1):81–9. Epub 1999/09/25. PMID:10496894.

34. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005; 365(9453):63–71. Epub 2005/10/28. jimmunol.1301903 [pii] doi:10.4049/jimmunol.1301903 PMID: 24154627.

35. Epub 2013/10/25. jimmunol.1301903 [pii] doi:10.4049/jimmunol.1301903 PMID: 24154627.

36. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013; 369(9):840–11. Epub 2013/08/30. doi: 10.1056/NEJMra1208623 PMID: 23984731.

37. Russwurm S, Vickers J, Meier-Hellmann A, Spangenberg P, Bredle D, Reinhart K, et al. Platelet and blood platelets. Circulation research. 1960; 8:234–9. Epub 1960/01/01. PMID: 13814510.

38. Shibazaki M, Kawabata Y, Yokochi T, Nishida A, Takada H, Endo Y. Complement-dependent accumulation and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides. Infect Immun. 1999; 67(10):5186–91. Epub 1998/09/25. PMID: 10496894.
47. De Backer D, Orbegozo Cortes D, Donadello K, Vincent JL. Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock. Virulence. 2014; 5(1):73–9. Epub 2013/09/27. 26482 [pii] doi:10.4161/viru.26482 PMID: 24067428.

48. Engellmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013; 13(1):34–45. Epub 2012/12/12. nri3345 [pii] doi:10.1038/nri3345 PMID: 23222502.

49. Secor D, Li F, Ellis CG, Sharpe MD, Gross PL, Wilson JX, et al. Impaired microvascular perfusion in sepsis requires activated coagulation and P-selectin-mediated platelet adhesion in capillaries. Intensive care medicine. 2010; 36(11):1928–34. Epub 2010/08/07. doi:10.1007/s00134-010-1969-3 PMID: 20689935.

50. Singer G, Urakami H, Specian RD, Stokes KY, Granger DN. Platelet recruitment in the murine hepatic microvasculature during experimental sepsis: role of neutrophils. Microcirculation. 2006; 13(2):89–97. Epub 2006/02/02. Q833747132766323 [pii] doi:10.1080/10739680500466343 PMID: 16459322.

51. Rahman M, Zhang S, Chew M, Ersson A, Jeppsson B, Thorlacius H. Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury. Ann Surg. 2009; 250(5):783–90. Epub 2009/10/07. doi:10.1097/SLA.0b013e3181bd95b7 PMID: 19806052.

52. Hwaiz R, Rahman M, Zhang E, Thorlacius H. Platelet secretion of CXCL4 is Rac1-dependent and regulates neutrophil infiltration and tissue damage in septic lung damage. British journal of pharmacology. 2015. Epub 2015/10/20. doi:10.1111/bph.13325 PMID: 26478565.

53. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006; 116(12):3211–9. Epub 2006/12/05. doi:10.1172/JCI29499 PMID: 17143330.

54. Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets. 2009; 20(1):50–7. Epub 2009/01/28. 90818673 [pii] doi:10.1080/09537100802503368 PMID: 19172522.

55. Seidel M, Winning J, Claus RA, Bauer M, Losche W. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thromb Haemost. 2009; 7(6):1030–2. Epub 2009/06/25. JTH3352 [pii] doi:10.1111/j.1538-7836.2009.03352.x PMID: 19548910.

56. Toner P, McAuley DF, Shyamsundar M. Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome. Crit Care. 2015; 19:374. Epub 2015/10/27. doi:10.1186/s13054-015-1091-6 PMID: 26494395.

57. Aoshiba K, Onizawa S, Tsuji T, Nagai A. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Critical care medicine. 2009; 37(3):889–98. Epub 2009/02/25. doi:10.1097/CCM.0b013e31819e8371 00000246-200903000-00013 [pii] PMID: 19237893.

58. Folman CC, Linthorst GE, van Mourik J, van Willigen G, de Jonge E, Levi M, et al. Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Thromb Haemost. 2000; 83(6):923–30. PMID: 10896250.

59. Wolber EM, Jelkmann W. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res. 2000; 20(5):499–506. PMID: 10841078.